{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:35:59Z","timestamp":1759412159672,"version":"3.40.5"},"reference-count":42,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE:<\/jats:title>\n                  <jats:p>In the international, placebo-controlled, Rotavirus Efficacy and Safety Trial, the pentavalent rotavirus vaccine reduced the rate of rotavirus-attributable hospitalizations and emergency department visits by 95%. This study investigated the effect in Jamaica.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>The vaccine effect on rates of hospitalizations and emergency department visits in Jamaica was evaluated in both modified intention-to-treat and per-protocol analyses. Rates of serious adverse events, including intussusception, also were compared between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>A total of 1804 Jamaican infants, 6 to 12 weeks of age at entry and primarily from low\/middle-income families of African heritage, received \u22651 dose. During the first year after dose 1, there were 2 and 11 hospitalizations or emergency department visits attributable to rotavirus gastroenteritis involving any serotype among 831 evaluable vaccine recipients and 809 evaluable placebo recipients, respectively (rate reduction: 82.2% [95% confidence interval: 15.1%\u201398.0%]). In the per-protocol analysis, all 8 G1 to G4 rotavirus-attributable events that occurred \u22652 weeks after dose 3 were in the placebo group (rate reduction: 100% [95% confidence interval: 40.9%\u2013100%]). Of the 1802 subjects included in the safety analyses, intussusception was confirmed for 1 vaccine recipient (115 days after the third dose) and 3 placebo recipients. One vaccine recipient and 3 placebo recipients died during the follow-up period, but none of the deaths was considered to be vaccine-related.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>In this posthoc subgroup analysis, the vaccine reduced health care resource utilization attributable to rotavirus gastroenteritis, without increased risk of intussusception or other serious adverse events, among infants in a resource-limited country.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2010-1240","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T05:12:07Z","timestamp":1291093927000},"page":"e1499-e1506","source":"Crossref","is-referenced-by-count":13,"title":["Pentavalent Rotavirus Vaccine in Developing Countries: Safety and Health Care Resource Utilization"],"prefix":"10.1542","volume":"126","author":[{"given":"Celia D. C.","family":"Christie","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Newton D.","family":"Duncan","sequence":"additional","affiliation":[{"name":"Surgery, Radiology, Anaesthesia, and Intensive Care, University of the West Indies, Kingston, Jamaica; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk A.","family":"Thame","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Onorato","sequence":"additional","affiliation":[{"name":"Departments of Clinical Research,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyacinth D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lavern G.","family":"Malcolm","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbin F.","family":"Itzler","sequence":"additional","affiliation":[{"name":"Health Economics, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark J.","family":"DiNubile","sequence":"additional","affiliation":[{"name":"Medical Communications, Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penny M.","family":"Heaton","sequence":"additional","affiliation":[{"name":"Departments of Clinical Research,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2010,12,1]]},"reference":[{"issue":"7","key":"2021121006593796500_B1","doi-asserted-by":"crossref","first-page":"e592","DOI":"10.1016\/j.ijid.2009.08.014","article-title":"Rotavirus disease burden, Nicaragua 2001\u20132005: defining the potential impact of a rotavirus vaccination program","volume":"14","author":"Amador","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"45","key":"2021121006593796500_B2","first-page":"1103","article-title":"Outbreak of severe rotavirus gastroenteritis among children: Jamaica, 2003","volume":"52","author":"Ashley","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2021121006593796500_B3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0035-9203(88)90294-5","article-title":"Laboratory investigations on rotavirus in infantile gastroenteritis in Jamaica","volume":"82","author":"Dowe","year":"1988","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"2021121006593796500_B4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3201\/eid0905.020562","article-title":"Global illness and deaths caused by rotavirus disease in children","volume":"9","author":"Parashar","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"2021121006593796500_B5","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1086\/605025","article-title":"Global mortality associated with rotavirus disease among children in 2004","volume":"200","author":"Parashar","year":"2009","journal-title":"J Infect Dis"},{"issue":"2","key":"2021121006593796500_B6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2105\/AJPH.78.2.149","article-title":"The quality of care is related to death rates: hospital inpatient management of infants with acute gastroenteritis in Jamaica","volume":"78","author":"Walker","year":"1988","journal-title":"Am J Public Health"},{"key":"2021121006593796500_B7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/605061","article-title":"Global rotavirus surveillance: determining the need and measuring the impact of rotavirus vaccines","volume":"200","author":"Widdowson","year":"2009","journal-title":"J Infect Dis"},{"issue":"20","key":"2021121006593796500_B8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMp0905091","article-title":"Defeating rotavirus? The global recommendation for rotavirus vaccination","volume":"361","author":"Danchin","year":"2009","journal-title":"N Engl J Med"},{"issue":"9619","key":"2021121006593796500_B9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(08)60524-3","article-title":"Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study","volume":"371","author":"Linhares","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"2021121006593796500_B10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"2021121006593796500_B11","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1056\/NEJMp0810154","article-title":"Rotavirus vaccines: early success, remaining questions","volume":"360","author":"Parashar","year":"2009","journal-title":"N Engl J Med"},{"issue":"21","key":"2021121006593796500_B12","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1001\/jama.2009.756","article-title":"Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua","volume":"301","author":"Patel","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"2021121006593796500_B13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa0905211","article-title":"Effect of rotavirus vaccination on death from childhood diarrhea in Mexico","volume":"362","author":"Richardson","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121006593796500_B14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"2021121006593796500_B15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMe0912141","article-title":"Rotavirus vaccine: a powerful tool to combat deaths from diarrhea","volume":"362","author":"Santosham","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121006593796500_B16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"N Engl J Med"},{"issue":"2","key":"2021121006593796500_B17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2009.10.041","article-title":"RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe","volume":"28","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"2021121006593796500_B18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-1246","article-title":"Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States","volume":"125","author":"Wang","year":"2010","journal-title":"Pediatrics"},{"key":"2021121006593796500_B19","unstructured":"United Nations Children's Fund. Country statistics: Jamaica. Available at: www.unicef.org\/infobycountry\/jamaica_statistics.html. Accessed June 27, 2004"},{"issue":"5","key":"2021121006593796500_B20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1086\/432549","article-title":"Rotavirus antigenemia in patients with acute gastroenteritis","volume":"192","author":"Fischer","year":"2005","journal-title":"J Infect Dis"},{"issue":"3","key":"2021121006593796500_B21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/INF.0b013e31818c0161","article-title":"Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity","volume":"28","author":"Ciarlet","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2021121006593796500_B22","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.inf.0000254391.71103.e8","article-title":"Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States","volume":"26","author":"Rodriguez","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"2021121006593796500_B23","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM200102223440804","article-title":"Intussusception among infants given an oral rotavirus vaccine","volume":"344","author":"Murphy","year":"2001","journal-title":"N Engl J Med"},{"key":"2021121006593796500_B24","first-page":"35","article-title":"Lifestyle as a measure of socio-economic status: the development of an instrument for use in Jamaica","volume":"31","author":"Leo-Rhynie","year":"1982","journal-title":"Soc Econ Stud"},{"issue":"1","key":"2021121006593796500_B25","first-page":"31","article-title":"Hydrostatic reduction of acute intussusceptions: a prospective study","volume":"47","author":"Duncan","year":"1998","journal-title":"West Indian Med J"},{"key":"2021121006593796500_B26","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1086\/605053","article-title":"Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua","volume":"200","author":"Orozco","year":"2009","journal-title":"J Infect Dis"},{"issue":"10","key":"2021121006593796500_B27","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/INF.0b013e3181782780","article-title":"Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine","volume":"27","author":"Ciarlet","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"22","key":"2021121006593796500_B28","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1016\/j.vaccine.2006.03.025","article-title":"Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants","volume":"24","author":"Vesikari","year":"2006","journal-title":"Vaccine"},{"issue":"9","key":"2021121006593796500_B29","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.vaccine.2008.12.059","article-title":"Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age","volume":"27","author":"Zaman","year":"2009","journal-title":"Vaccine"},{"issue":"5","key":"2021121006593796500_B30","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1542\/peds.2009-0466","article-title":"Prevention of rotavirus disease: updated guidelines for use of rotavirus vaccine","volume":"123","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2009","journal-title":"Pediatrics"},{"issue":"2","key":"2021121006593796500_B31","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-1021","article-title":"Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States","volume":"125","author":"Boom","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"2021121006593796500_B32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.vaccine.2009.10.075","article-title":"Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine","volume":"28","author":"Chang","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"2021121006593796500_B33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CVI.00382-08","article-title":"Decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine","volume":"16","author":"Clark","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"2021121006593796500_B34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1086\/649843","article-title":"Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil","volume":"201","author":"Correia","year":"2010","journal-title":"J Infect Dis"},{"issue":"3","key":"2021121006593796500_B35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1586\/14760584.7.3.345","article-title":"Rotavirus vaccine introduction in the Americas: progress and lessons learned","volume":"7","author":"de Oliveira","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"2021121006593796500_B36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1542\/peds.2008-3528","article-title":"Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine","volume":"124","author":"Tate","year":"2009","journal-title":"Pediatrics"},{"key":"2021121006593796500_B37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2334-8-103","article-title":"Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico","volume":"8","author":"Valencia-Mendoza","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"3","key":"2021121006593796500_B38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0b013e3181be6257","article-title":"Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses","volume":"29","author":"Goveia","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2021121006593796500_B39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/INF.0b013e318168d29e","article-title":"Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency","volume":"27","author":"Goveia","year":"2008","journal-title":"Pediatr Infect Dis J"},{"issue":"9741","key":"2021121006593796500_B40","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"issue":"9741","key":"2021121006593796500_B41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2021121006593796500_B42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/QCO.0b013e32833040a9","article-title":"Rotavirus vaccines for the developing world","volume":"22","author":"O'Ryan","year":"2009","journal-title":"Curr Opin Infect Dis"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/126\/6\/e1499\/1055521\/zpe012100e1499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/126\/6\/e1499\/1055521\/zpe012100e1499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T16:09:47Z","timestamp":1639152587000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/126\/6\/e1499\/64982\/Pentavalent-Rotavirus-Vaccine-in-Developing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,1]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2010,12,1]]},"published-print":{"date-parts":[[2010,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2010-1240","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2010,12,1]]}}}